Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule therapeutics that target fundamental biological pathways in cancer. Utilizing its proprietary Integrated Discovery Engine, Zentalis aims to identify unique targets and develop novel, potentially best-in-class new chemical entities (NCEs) with differentiated product profiles.
The company's robust pipeline is highlighted by two lead product candidates: ZN-c5 and ZN-c3. ZN-c5 is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, while ZN-c3 targets advanced solid tumors and ovarian cancer. Zentalis is also developing azenosertib (ZN-c3), a WEE1 inhibitor, as a monotherapy and in combination with other agents to address multiple tumor types.
Recently, Zentalis announced plans to use the net proceeds from its latest offering to fund ongoing and planned clinical trials, as well as for working capital and other general corporate purposes. The company’s financial strategy is designed to support its operational expenses and capital expenditure requirements through 2026.
The company’s latest financial disclosures highlighted strong clinical data for azenosertib, showing an objective response rate of 36.8% in ovarian cancer and uterine serous carcinoma patients. Azenosertib, currently in multiple clinical trials, demonstrated encouraging efficacy both as a monotherapy and in combination with chemotherapy.
Headquartered in New York and San Diego, Zentalis is collaborating with top financial institutions like Morgan Stanley, Jefferies, and Guggenheim Securities to drive its growth. The company's strong cash position is bolstered by its recent offerings and ongoing support from financial advisors.
Continuing to advance its clinical strategies, Zentalis is focused on its fast-to-market approach for azenosertib, aiming to submit its first NDA in gynecologic malignancies by 2026. Furthermore, Zentalis is leveraging its expertise in cancer biology and medicinal chemistry to explore the potential of protein degraders and other innovative treatment modalities.
Stay updated on Zentalis Pharmaceuticals’ latest developments by visiting their official website or following them on social media platforms such as Twitter and LinkedIn.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced promising initial data on ZN-c3, a Wee1 inhibitor, from ongoing trials in advanced ovarian cancer and uterine serous carcinoma. The company received a $25 million equity investment from Pfizer to advance clinical development for ZN-c3 and ZN-d5. A Phase 1/2 study for ZN-d5 in relapsed AL amyloidosis has been initiated. As of March 31, 2022, Zentalis reported cash and marketable securities of $289.4 million, providing a cash runway into Q1 2024 after budget reallocations following the Pfizer investment.
Zentalis Pharmaceuticals has entered into a joint clinical development agreement with Pfizer for ZN-c3, a selective Wee1 inhibitor aimed at treating cancer. This partnership includes a $25 million investment from Pfizer through a share offering, expected to close on April 29, 2022. The funding extends Zentalis’ cash runway into Q1 2024, enabling continued clinical trials. Additionally, Pfizer's Adam Schayowitz will join Zentalis’ Scientific Advisory Board to enhance strategic clinical development. The company retains full ownership of its pipeline.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) recently presented promising clinical data for its lead candidate, ZN-c3, at the AACR Annual Meeting. The combination of ZN-c3 with chemotherapy showed an objective response rate (ORR) of 30.2% in advanced ovarian cancer patients. Additionally, in patients with uterine serous carcinoma (USC), ZN-c3 achieved a 27.3% ORR and a 90.9% disease control rate with notable tolerability. The results suggest ZN-c3's potential as a significant therapeutic option in treating advanced cancers.
Zentalis Pharmaceuticals has announced promising results from its ongoing Phase 1b trial of ZN-c3, a potential best-in-class Wee1 inhibitor, in combination with chemotherapy for platinum-resistant ovarian cancer. The treatment demonstrated an overall response rate (ORR) of 30.2% across all evaluated chemotherapy cohorts, with the highest cohort reaching 62.5%. ZN-c3 showed good tolerability, exhibiting a better safety profile than other Wee1 inhibitors. The company plans to advance to a Phase 3 trial based on these results.
Zentalis Pharmaceuticals has announced a strategic collaboration with Caris Life Sciences to enhance patient recruitment for its clinical trials. This partnership will utilize Caris’ advanced molecular profiling to identify candidates for Zentalis’ oncology studies, particularly focusing on the Wee1 inhibitor ZN-c3. Both companies aim to leverage comprehensive genomic data to improve therapeutic development. Zentalis retains full ownership of its candidates while pursuing innovative cancer treatments.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the dosing of its first patient in a Phase 1/2 trial for ZN-d5, an oral selective BCL-2 inhibitor, targeting relapsed or refractory light chain (AL) amyloidosis. This trial (ZN-d5-003) aims to evaluate the safety, efficacy, and pharmacokinetics of ZN-d5 in patients with this rare and life-threatening condition. AL amyloidosis affects ~75,000 people globally, causing severe organ damage with limited treatment options. Zentalis aims to provide a potentially best-in-class therapy to address this unmet need.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will present at the Oppenheimer Annual Healthcare Conference on March 16, 2022, at 10:00 a.m. ET. The presentation will be accessible via a live webcast on the company’s website, with an archived version available afterward. Zentalis focuses on developing small molecule therapeutics for cancer treatment, with a promising pipeline including ZN-c3 (Wee1 inhibitor), ZN-c5 (SERD), and ZN-d5 (BCL-2 inhibitor). The company operates from New York and San Diego.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) will present updated data from the Phase 1 expansion cohort of its Wee1 inhibitor ZN-c3 for uterine serous carcinoma (USC) at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. The company highlights five accepted abstracts, including a mini symposium detailing ZN-c3's efficacy and safety. CEO Dr. Anthony Sun expressed optimism about the ongoing trials, noting ZN-c3's promising durability and tolerability. The company aims to explore ZN-c3's potential in combination therapies.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) received Fast Track designation from the FDA for its Wee1 Inhibitor, ZN-c3, targeting uterine serous carcinoma. The company has launched two new trials for ZN-c3 and added a preclinical BCL-xL heterobifunctional degrader candidate to its pipeline. As of December 31, 2021, Zentalis reported $339.9 million in cash and equivalents, which is expected to fund operations into Q3 2023. R&D expenses rose to $175.6 million, indicating intensified clinical pipeline advancements.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a biopharmaceutical firm, announced CEO Anthony Sun's participation in virtual investor conferences. The events include the Guggenheim Oncology Conference on February 10, 2022, at 10:30 a.m. EST, and the SVB Leerink 2022 Global Healthcare Conference on February 17, 2022, at 1:00 p.m. EST. Webcasts will be available on Zentalis's website post-event. The company focuses on developing innovative cancer therapies, including ZN-c3, ZN-c5, ZN-d5, and ZN-e4, targeting various cancer types.
FAQ
What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?
What is the market cap of Zentalis Pharmaceuticals (ZNTL)?
What products is Zentalis Pharmaceuticals currently developing?
What is the purpose of Zentalis Pharmaceuticals' recent financial offering?
What is azenosertib and why is it significant?
Where are Zentalis Pharmaceuticals' main operations located?
Who are Zentalis Pharmaceuticals' financial collaborators?
What is Zentalis’ Integrated Discovery Engine?
When does Zentalis plan to submit its first NDA for azenosertib?
What are the recent clinical achievements of Zentalis Pharmaceuticals?
How does Zentalis plan to use its expertise in cancer biology?
Where can one access more information about Zentalis Pharmaceuticals?
